Logan L A, Cripps M C, Hirte W E, Rapp E F
Can J Surg. 1982 Sep;25(5):581-4.
To evaluate the usefulness of the estrogen receptor test as a prognostic indicator, a retrospective study of 134 patients with primary breast cancer was carried out at the Ottawa Civic Hospital. The estrogen receptor values, measured in a single laboratory, were correlated with the recurrence rate and the survival time after recurrence. Other well-established prognostic data, such as stage of cancer, lymph-node involvement and menopausal state, have been similarly examined to ensure that information obtained from the estrogen receptor test offers more than a duplication of information from these traditional methods. It was found that this test is a useful prognostic tool when used on premenopausal women. The results of the study show that (a) breast cancer patients having positive estrogen receptor values have recurrences less frequently, (b) among estrogen receptor-negative patients there is more than a 50% chance of early recurrence in premenopausal women compared with less than a 20% chance in postmenopausal women, (c) conventional adjuvant chemotherapy in estrogen receptor-negative premenopausal patients does not prevent early recurrence, hence, this group requires more aggressive adjuvant treatment and (d) the method described by Heuson and colleagues for estrogen receptor determination follows the trends of better-established tests.
为评估雌激素受体检测作为一种预后指标的实用性，渥太华市民医院对134例原发性乳腺癌患者进行了一项回顾性研究。在单一实验室测量的雌激素受体值与复发率及复发后的生存时间相关联。其他已确立的预后数据，如癌症分期、淋巴结受累情况和绝经状态，也进行了类似的检查，以确保从雌激素受体检测中获得的信息不仅仅是这些传统方法所提供信息的重复。研究发现，该检测用于绝经前女性时是一种有用的预后工具。研究结果表明：(a) 雌激素受体值呈阳性的乳腺癌患者复发频率较低；(b) 在雌激素受体阴性的患者中，绝经前女性早期复发的几率超过50%，而绝经后女性则不到20%；(c) 雌激素受体阴性的绝经前患者进行传统辅助化疗并不能预防早期复发，因此，该组患者需要更积极的辅助治疗；(d) 赫森及其同事描述的雌激素受体测定方法与更成熟检测方法的趋势一致。
